Our website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
Scientist with laboratory background and concept.

British Patient Capital and Mubadala Invest in SV Biotech Crossover Opportunities Fund

British Patient Capital and Mubadala Investment Company (Mubadala), an Abu Dhabi-based sovereign investor, today announced their investment into the SV Biotech Crossover Opportunities Fund (SV BCOF). The co-investment between the two entities is being made through the UK’s Life Sciences Investment Programme (LSIP), which was launched in 2021 to support the growth of UK life sciences businesses.

Managed by SV Health Investors, SV BCOF is targeting growth-stage, biotechnology companies developing transformative therapies. The fund has a significant focus on the UK and aims to invest in businesses that have the potential to positively impact society by addressing major unmet clinical needs. British Patient Capital is a cornerstone investor in the fund and has committed a total of $48.6m.

To date, six investments have been completed through SV BCOF, including five into UK-based companies: Bicycle, a company developing a brand-new class of precision-guided therapeutics to target intractable cancers; Quell Therapeutics, a specialist in engineered T-regulatory cell therapies for serious medical conditions driven by overactivity of the immune system; Pulmocide, a biopharmaceutical company treating common but hard-to-treat respiratory infections; and EyeBio, which is developing a new generation of therapies for eye diseases to protect, restore, and improve vision for people who are underserved by available therapies. Nimbus Therapeutics, one of the fund’s portfolio companies, has also recently announced the sale to Takeda of an asset which addresses multiple immune-mediated diseases. The agreement represents Takeda’s largest ever single-asset purchase with Nimbus to receive $4bn upfront and a potential further $2bn in commercial milestone payments.

Catherine Lewis La Torre, CEO of British Patient Capital, said: “The UK is a world leader in life sciences. The discovery and development of new drugs, vaccines, and cell and gene therapies have placed the UK at the frontier of responses to global challenges such as the Covid-19 pandemic, ageing populations and the provision of sustainable healthcare. Yet there is a clear lack of later-stage funds investing consistently at scale into the life sciences sector, which means some of our most promising businesses are either acquired early or forced to move elsewhere.

The Life Sciences Investment Programme was established to address this gap, and I am delighted to announce this investment into the SV Biotech Crossover Opportunities Fund. This is the first growth stage biotech vehicle managed by SV Health Investors, a firm which has a long track record in supporting dynamic life sciences businesses. By investing in this fund, British Patient Capital is backing innovation and helping to ensure that the UK’s high-potential biotech companies are able to fulfil their potential at home, supporting the UK’s position as a science superpower.”

Mohammed Al-Huraimel Al-Shamsi, Head of UK Investment Programme, Mubadala, said: “Healthcare innovation is a critical priority which can be addressed with a global investment approach. We are pleased to announce our next investment through our life sciences programme, launched to support the development of new technologies, research and talent to advance the UK’s life sciences sector. This investment is an important part of our strategy to offer much needed support for next generation innovative life sciences businesses that have the potential for significant and sustainable growth. SV Health Investors is a market leader in its sector with its differentiated proposition and impressive track record, and is a welcome addition to Mubadala’s growing portfolio in the UK. We look forward to supporting this ambitious team on their next phase of growth.”

Houman Ashrafian, Managing Partner, SV Health Investors, said: “SV BCOF represents an extension of our existing strategy and the investments made by the Fund will aim to boost high potential companies, supporting them in generating the clinical data required to deliver life changing therapeutics to patients with high unmet medical needs. SV is able to provide this support thanks to our expert and proven team of life sciences entrepreneurs including the industry veterans who make up our Venture Partner network. Our work is also made possible by our valued investors. We remain grateful to British Patient Capital for their continued support of SV and we are excited to welcome Mubadala as a new LP into SV BCOF.”

The Life Sciences Investment Programme (LSIP) is a £200m initiative managed by British Patient Capital designed to address the growth equity finance gap faced by high-potential UK life sciences companies. This is expected to attract at least a further £400m of private investment. Through LSIP, we make cornerstone commitments to later stage life sciences venture growth funds with a strong UK focus, typically investing between £50m and £100m in each successful fund.